Previous 10 | Next 10 |
2024-03-13 14:55:38 ET More on Cue Biopharma Cue Biopharma: Not Exactly Sinking The Money Ball Yet Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma Read the full ...
Cue Biopharma, Inc. (NASDAQ: CUE) is one of today's top gainers. The company's shares have moved 19.77% on the day to $2.12. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of canc...
2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company’s lead clinical asset, CUE-101, w...
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healt...
2024-01-09 05:05:30 ET Summary Cue Biopharma is a biotech focused on developing immunogenic peptides to fight specific diseases, particularly cancers. CUE's most advanced project, CUE-101, has shown favorable early results in a phase 1 trial for recurrent or metastatic head and ne...
2023-12-14 07:04:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cue Biopharma (NASDAQ: CUE ) just reported results for the third quarter of 2023. Cue Biopharma reported earnings per share of -24 cents. This was above the analyst estima...
BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities H...
2023-11-11 15:32:08 ET Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Conference Call November 9, 2023 04:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann M...
Cue Biopharma Inc. (CUE) is expected to report $-0.3 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Cue Biopharma Inc. Company Name:
CUE Stock Symbol:
NASDAQ Market:
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first qua...
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the ...
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citi...